Home › Diffuse Large B-Cell Lymphoma › Kentucky
Diffuse Large B-Cell Lymphoma clinical trials in Kentucky
11 studies for Diffuse Large B-Cell Lymphoma are looking for participants at sites in Kentucky.
Cities in Kentucky
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Saint Elizabeth Medical Center Edgewood ( Site 0141), Edgewood
- Baptist Health Hardin ( Site 0154), Elizabethtown
- Baptist Health Lexington ( Site 0127), Lexington
- and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06890884A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- Saint Elizabeth Medical Center Edgewood ( Site 0165), Edgewood
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05139017A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- University of Kentucky ( Site 0106), Lexington
- Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0163), Louisville
- Owensboro Medical Health System ( Site 0195), Owensboro
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06717347A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- University of Kentucky, Lexington
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06091865Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- University of Kentucky - Markey Cancer Center, Lexington
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT06806033Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- University of Kentucky Medical Center, Lexington
- University of Louisville Health Brown Cancer Center, Louisville
- Norton Cancer Institute, Louisville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 31, 2026 · NCT06500273A Study of ARC-02 in B-cell NHL
- Norton Cancer Institute, Louisville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 26, 2026 · NCT07691606Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- University of Louisville Brown Cancer Center, Louisville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT05826535A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- University of Louisville Health, Louisville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT07188558The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- Norton Cancer Institute, Louisville
RecruitingPhase 1/2
Ages 12 to 95 · All sexes · Updated Apr 15, 2026 · NCT04329728Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 2, 2026 · NCT05633615From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.